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Abstract
Background: We have recently reported that the expression of peptidylarginine deiminase 2 (PADI2) is regulated
by EGF in mammary cancer cells and appears to play a role in the proliferation of normal mammary epithelium;
however, the role of PADI2 in the pathogenesis of human breast cancer has yet to be investigated. Thus, the goals
of this study were to examine whether PADI2 plays a role in mammary tumor progression, and whether the
inhibition of PADI activity has anti-tumor effects.
Methods: RNA-seq data from a collection of 57 breast cancer cell lines was queried for PADI2 levels, and
correlations with known subtype and HER2/ERBB2 status were evaluated. To examine PADI2 expression levels
during breast cancer progression, the cell lines from the MCF10AT model were used. The efficacy of the PADI
inhibitor, Cl-amidine, was tested in vitro using MCF10DCIS cells grown in 2D-monolayers and 3D-spheroids, and
in vivo using MCF10DCIS tumor xenografts. Treated MCF10DCIS cells were examined by flow-cytometry to
determine the extent of apoptosis and by RT2 Profiler PCR Cell Cycle Array to detect alterations in cell cycle
associated genes.
Results: We show by RNA-seq that PADI2 mRNA expression is highly correlated with HER2/ERBB2 (p = 2.2 × 106) in
luminal breast cancer cell lines. Using the MCF10AT model of breast cancer progression, we then demonstrate that
PADI2 expression increases during the transition of normal mammary epithelium to fully malignant breast
carcinomas, with a strong peak of PADI2 expression and activity being observed in the MCF10DCIS cell line, which
models human comedo-DCIS lesions. Next, we show that a PADI inhibitor, Cl-amidine, strongly suppresses the
growth of MCF10DCIS monolayers and tumor spheroids in culture. We then carried out preclinical studies in nude
(nu/nu) mice and found that Cl-amidine also suppressed the growth of xenografted MCF10DCIS tumors by more
than 3-fold. Lastly, we performed cell cycle array analysis of Cl-amidine treated and control MCF10DCIS cells, and
found that the PADI inhibitor strongly affects the expression of several cell cycle genes implicated in tumor
progression, including p21, GADD45α, and Ki67.
Conclusion: Together, these results suggest that PADI2 may function as an important new biomarker for
HER2/ERBB2+ tumors and that Cl-amidine represents a new candidate for breast cancer therapy.
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Background
PADIs are a family of posttranslational modification
enzymes that convert positively charged arginine resi-
dues on substrate proteins to neutrally charged citrul-
line, and this activity is alternatively called citrullination
or deimination. The PADI enzyme family is thought to
have arisen by gene duplication and localizes within the
genome to a highly organized cluster at 1p36.13 in
humans. At the protein level, each of the five well-
conserved PADI members shows a relatively distinct pat-
tern of substrate specificity and tissue distribution [1,2].
Increasingly, the dysregulation of PADI activity is asso-
ciated with a range of diseases, including rheumatoid
arthritis (RA), multiple sclerosis, ulcerative colitis, neural
degeneration, COPD, and cancer [3-5]. While the pre-
sumptive function of PADI activity in most diseases is
linked to inflammation, the role that PADIs play in can-
cer progression is not clear. We and others, however,
have found that PADI4 appears to play a role in gene
regulation in cancer cells via histone tail citrullination.
For example, in MCF7 breast cancer cells estrogen
stimulation enhances PADI4 binding and histone H4
citrullination at the canonical ER target gene, TFF1,
leading to transcriptional repression [6]. On the other
hand, stimulation of MCF7 cells with EGF facilitates ac-
tivation of c-fos via PADI4-mediated citrullination of the
ELK1 oncogene [7]. Additionally, others have shown that
citrullination of the p53 tumor suppressor protein affects
the expression of p53 target genes p21, OKL38, CIP1
and WAF1 [8-10]. Interestingly, treatment of several
PADI4-expressing cancer cell lines with the PADI inhibi-
tor, Cl-amidine, elicited strong cytotoxic effects while
having no observable effect on non-cancerous lines [11],
suggesting that PADIs may represent targets for new
cancer therapies.
Our current study suggests that PADI2 may also play
a role in cancer progression, and this prediction is sup-
ported by several previous studies. For example, a mouse
transcriptomics study investigating gene expression in
MMTV-neu tumors found that PADI2 expression was
upregulated ~2-fold in hyperplastic, and ~4-fold in pri-
mary neu-tumors, when compared to matched normal
mammary epithelium [12]. In humans, PADI2 is one of
the most upregulated genes in luminal breast cancer cell
lines compared to basal lines [13,14]. Additionally, gene
expression profiling of 213 primary breast tumors with
known HER2/ERBB2 status identified PADI2 as one of
29 overexpressed genes in HER2/ERBB2+ tumors; thus,
helping to define a HER2/ERBB2+ gene expression sig-
nature [15]. Given these previous studies, our goal was
to formally test the hypothesis that PADI2 plays a role in
mammary tumor progression. For the study, we first
documented PADI2 expression and activity during mam-
mary tumor progression, and then investigated the
effects of PADI inhibition in cell cultures, tumor sphe-
roids, and preclinical in vivo models of breast cancer.
Methods
Cell culture and treatment with Cl-amidine
The MCF10AT cell line series (MCF10A, MCF10AT1kC1.2,
MCF10DCIS.com, and MCF10CA1aC1.1) was obtained
from Dr. Fred Miller (Barbara Ann Karmanos Cancer
Institute, Detroit, MI, USA). This biological system has
been extensively reviewed [16,17] and culture conditions
described [18-20]. The MCF7, BT-474, SK-BR-3, and
MDA-MB-231 cell lines were from obtained from ATCC
(Manassas, VA, USA) and cultured according to ma-
nufacturer’s directions. All cells were maintained in a
humidified atmosphere of 5% CO2 at 37°C. For the ex-
perimental treatment of cell lines with Cl-amidine, cells
were seeded in 6-well plates (2 × 104) and collected by
trypsinization 5d post-treatment. Counts were perfor-
med using a Coulter counter (Beckman Coulter, Fullerton,
CA, USA) and are represented as mean fold difference in
cell number after treatment. Cl-amidine was synthesized
as previously described [21].
MMTV mice and the generation of MCF10DCIS xenografts
and multicellular tumor spheroids
Tissues from the MMTV-neu mouse were a generous
gift from Dr. Robert S. Weiss, Cornell University, and
the MMTV-Wnt-1 hyperplastic mammary glands and
tumors were a gift of Dr. Louise R. Howe, Weill Cornell
Medical College. MCF10DCIS xenograft tumors were
generated by injecting 1 × 106 cells in 0.1 mL Matrigel
(1:1) (BD Biosciences, San Jose, CA, USA) subcutane-
ously near the nipple of gland #3 in 6-week old female
nude (nu/nu) mice (Taconic, Germantown, NY, USA).
When the tumors reached ~200 mm3, intraperitoneal
injections of Cl-amidine (50 mg/kg/day) or vehicle con-
trol (PBS) were initiated and carried out for 14 days.
Tumor volume was calculated by the formula: (mm3) =
(d2 × D)/2, where “d” and “D” are the shortest and long-
est diameters of the tumor, respectively. Tumor volume
was measured weekly by digital caliper, and the differ-
ences between tumor volumes were evaluated by the
non-parametric Mann–Whitney–Wilcoxon (MWW)
test. Results are reported as mean ± SD. After 14 days,
tumors were removed and either snap-frozen, placed in
RNAlater (Qiagen Inc., Valencia, CA, USA), or added
to 10% buffered formalin. Seven mice per group were
used for each treatment. All mouse experiments were
reviewed and approved by the Institutional Animal Care
and Use Committees (IACUC) at Cornell University.
Multicellular tumor spheroids were generated using the
liquid overlay technique as previously described [22-24].
The spheroids were allowed to form over 48h and main-
tained up to 6–10 days for morphological analysis, then
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collected, rinsed with phosphate buffered saline, and
fixed in 10% buffered formalin.
Assay of PADI activity
Cell lines were assayed for PADI activity as previously
described [25,26]. Briefly, citrulline levels were deter-
mined using BAEE (α-N-benzoyl-L-arginine ethyl ester)
as a substrate. After incubating lysates for 1h at 50°C
with BAEE substrate mixture, the reaction was stopped
by the addition of perchloric acid. The perchloric acid-
soluble fraction was subjected to a colorimetric reaction
with citrulline used as a standard and absorbance mea-
sured at 464 nm.
Immunohistochemistry (IHC) and immunofluorescence (IF)
IHC and IF experiments were carried out using a stand-
ard protocol as previously described [27]. Primary anti-
bodies are as follows: anti-PADI2 1:100 (ProteinTech,
Chicago, IL, USA), anti-ERBB2 (A0485) 1:100 (Dako,
Carpentaria, CA, USA), anti-Cytokeratin 1:100 (Dako),
and anti-p63 1:100 (Abcam, Cambridge, MA, USA). Sec-
tions prepared for IHC were incubated in DAB chro-
magen solution (Vector Laboratories, Burlingame, CA,
USA) according to the manufacturer’s protocol, washed,
and then counterstained with hematoxylin. The IF slides
were incubated in streptavidin conjugated-488 (Invitro-
gen, Carlsbad, CA, USA), washed, and then mounted
using Vectashield containing DAPI (Vector Laboratories).
Negative controls for both IHC and IF experiments were ei-
ther rabbit or mouse IgG antibody at the appropriate con-
centrations. Tumor sections were examined for general
morphological differences after hematoxylin and eosin
(H&E) staining. Basement membrane integrity was deter-
mined using periodic acid-Schiff (PAS) stained slides, and
was scored by SM on a scale of 0–3: 0- continuous with no
breaching, 1- a few small interruptions, 2- several interrup-
tions with breaching by tumor cells, 3- extensive loss of
basement membrane with invasion of tumor cells over the
breached area; observations were performed under 10X
magnification.
Immunoblotting
Immunoblotting was carried out as previously described
[27]. Primary antibodies were incubated overnight at 4°C
using the following concentrations: anti-PADI2 1:1000
(ProteinTech) and anti-ErbB2 1:5000 (Dako). To confirm
equal protein loading, membranes were stripped and re-
probed with anti-β-actin 1:5000 (Abcam).
Quantitative real-time PCR (qRT-PCR)
RNA was purified using the Qiagen RNAeasy kit, inclu-
ding on-column DNAse treatment to remove genomic
DNA. The resulting RNA was reverse transcribed using
the ABI High Capacity RNA to cDNA kit according to
the manufacturer’s protocol (Applied Biosystems, Foster
City, CA, USA). TaqMan Gene Expression Assays (ABI)
for human PADI2 (Hs00247108_m1) and GAPDH
(4352934E) were used for qRT-PCR. Data were analyzed
by the 2 -ΔΔ C(t) method [28]. Data are shown as means
± SD from three independent experiments, and were
separated using Student’s t-test. For the analysis of cell
cycle gene expression, cDNA was synthesized (RT2 First
Strand Kit, Qiagen) and samples analyzed for expression
of 84 genes involved in cell cycle regulation by RT2 Pro-
filer PCR Cell Cycle Array (PAHS-020A, Qiagen). For
data analysis, the RT2 Profiler PCR Array software pack-
age was used and statistical analyses performed (n = 3).
This package uses ΔΔ CT–based fold change calcula-
tions and the Student’s t-test to calculate two-tail, equal
variance p-values.
Flow-cytometry
Monolayers of MCF10DCIS and MCF10A cells were
seeded into 25 cm2 flasks (2 × 106 cells) and treated with
either Cl-amidine (200 μM or 400 μM), or 10μg/mL
tunicamycin (apoptosis positive control). BT-474, SK-
BR-3, and MDA-MB-231 cell lines were treated as previ-
ously described for MCF10DCIS and MCF10A; however,
they were also treated with 100 μM Cl-amidine. Cells
were harvested after 4d using Accutase (Innovative Cell
Technologies, Inc, San Diego, CA, USA), fixed, then per-
meabilized, and blocked in FACS Buffer (0.1M Dulbec-
co’s phosphate buffered saline, 0.02% sodium azide, 1.0%
bovine serum albumin, and 0.1% Triton X-100) contai-
ning 10% normal goat serum and stained (except the
isotype controls) with rabbit anti-cleaved Caspase-3 anti-
body (Cell Signaling Technology, Inc, Danvers, MA,
USA). Isotype controls were treated with normal rabbit
IgG (Vector Laboratories) at 4 μg/mL. All samples were
stained with secondary goat anti-rabbit IgG conjugated
to Alexa-488 (Invitrogen) and DAPI (Invitrogen) accord-
ing to the manufacturer’s instructions. Cells were ana-
lyzed on a FACS-Calibur (BD Biosciences) or a Gallios
(Beckman Coulter) flow-cytometer and data analyzed for
percent apoptotic cells (cleaved Caspase-3+) and cell cycle
analysis with FlowJo software (TreeStar, Inc, Ashland, OR,
USA). Data are shown as means ± SD from three in-
dependent experiments, and were separated using
Student’s t-test.
RNA-seq analysis of breast cancer cell lines
Whole transcriptome shotgun sequencing (RNA-seq)
was completed on breast cancer cell lines and expression
analysis was performed with the ALEXA-seq software
package as previously described [29]. Briefly, this ap-
proach comprises (i) creation of a database of expression
and alternative expression sequence ‘features’ (genes,
transcripts, exons, junctions, boundaries, introns, and
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intergenic sequences) based on Ensembl gene models,
(ii) mapping of short paired-end sequence reads to these
features, (iii) identification of features that are expressed
above background noise while taking into account locus-
by-locus noise. RNA-seq data was available for 57 lines
(17 basal, 5 basal-NM, 6 claudin-low, 29 luminal). An
average of 70.6 million (76bp paired-end) reads passed
quality control per sample. Of these, 53.8 million reads
mapped to the transcriptome on average, resulting in an
average coverage of 48.2 across all known genes. Log2
transformed estimates of gene-level expression were
extracted for analysis with corresponding expression sta-
tus values indicating whether the genes were detected
above background level.
Statistical analysis
All experiments were independently repeated at least
three times unless otherwise indicated. Values were
expressed as the mean ± the SD. Means were separated
using Student’s t-test or by Mann—Whitney-Wilcoxon
(MWW) test, with a p-value less than 0.05 considered as
significantly different. Subtype specific expression in the
RNA-seq analysis was determined by Wilcoxon signed-
rank test. Correlations were determined by Spearman
rank correlation. Genes were considered significantly dif-
ferentially expressed or correlated if they had a p-value
less than 0.05.
Results
PADI2 is overexpressed in transformed cells of the
MCF10AT model of breast cancer progression
In order to investigate PADI2 expression during tumor
progression, we first utilized TaqMan quantitative real-
time PCR (qRT-PCR) to measure PADI2 mRNA levels
in cells from the MCF10AT tumor progression series
(Figure 1a). As shown previously, these cell lines closely
model the progression from normal (MCF10A), to
hyperplastic (MCF10AT), to ductal carcinoma in situ
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Figure 1 PADI2 expression is highest in MCF10DCIS.com cells in the MCF10AT model of breast cancer progression. (a) The MCF10AT
model is a series of cell lines that recapitulates the transition from normal epithelium to malignant carcinoma. (b and c) PADI2 mRNA and protein
expression is increased in transformed cells of the MCF10AT model, with very high levels seen in MCF10DCIS cells. Total RNA was isolated and
PADI2 mRNA levels were determined by qRT-PCR (TaqMan) using MCF10A cells as a reference and GAPDH normalization. Data were analyzed
using the 2 -ΔΔ C(t) method and are expressed as the mean ± SD from three independent experiments (* p < 0.001). PADI2 expression levels were
evaluated by subjecting whole cell lysates to SDS-PAGE and immunoblot analysis using an anti-PADI2 antibody. HER2/ERBB2 expression levels,
detected using an anti-HER2 antibody, are also upregulated in the transformed cell lines when compared to the MCF10A levels. The blot was
stripped and equal protein loading was determined by probing with a β-actin antibody. (d) Citrulline levels in the cell lines were determined by
citrullination enzymatic assays, with the highest level of activity measured in the MCF10DCIS cells. Briefly, cell lysates were incubated with PADI
substrate BAEE, and the reaction stopped with perchloric acid. The perchloric acid-soluble fraction was subjected to a colorimetric reaction with
citrulline used as a standard and absorbance measured at 464 nm.
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(DCIS) with necrosis (MCF10DCIS.com), and finally
to invasive/metastatic (MCF10CA1) breast cancer
[16,17,30]. Results (Figure 1b) show that PADI2 mRNA
expression is elevated in the transformed cell lines,
with the highest levels found in the comedo-DCIS
MCF10DCIS.com cell line (hereafter MCF10DCIS).
Additionally, PADI2 protein levels closely correlated
with PADI2 mRNA levels across these lines, with the
highest levels of PADI2 protein observed in the
MCF10DCIS line. Given the previous microarray studies
correlating PADI2 expression with HER2/ERBB2, we
also probed this cell line series with a well-characterized
HER2/ERBB2 antibody and found that HER2/ERBB2
levels were also elevated in the transformed cell lines
compared to the non-tumorigenic "normal" MCF10A
line (Figure 1c). We also tested whether the increase in
PADI2 expression correlated with PADI2 enzymatic ac-
tivity, with results (Figure 1d) showing that citrulline
levels are, in fact, highest in the MCF10DCIS cell
line; therefore, indicating a strong correlation between
increased PADI2 expression and enzymatic activity.
While these cell lines have been previously classified as
basal-like [31], both MCF10A and MCF10DCIS have
been shown to possess bipotential progenitor properties
[19,32,33]. Furthermore, the MCF10AT cells have been
reported to show the same multipotent properties [34],
but until recently, there has only been one other report
showing that HER2/ERBB2 is upregulated in the trans-
formed lines of this series [35]. These data suggest that
PADI2 activity may play a role in mammary tumor pro-
gression and that PADI2-mediated citrullination may be
particularly relevant to comedo-DCIS biology.
Levels of PADI2 correlate with the luminal breast cancer
subtype and HER2/ERBB2 overexpression
To test whether PADI2 displays a restricted expression
pattern with respect to breast cancer subtype, we next
investigated PADI2 mRNA and protein expression in cell
lines representing four common breast cancer subtypes:
MCF7 (luminal A), BT-474 (luminal B), SK-BR-3
(HER2/ERBB2+), and MDA-MB-231 (basal). At the pro-
tein level, PADI2 was observed in both BT-474 (ER+, PR+,
HER2/ERBB2+) and SK-BR-3 (ER-, PR-, and HER2/ERBB2
overexpressing) cell lines. Interestingly, the comparison of
PADI2 and HER2/ERBB2 protein levels across these four
cell lines supports the hypothesis that these two proteins
are coexpressed (Figure 2a). While the PADI2 pro-
tein expression is not observed in MCF7 cells in
Figure 2a, a longer exposure of this blot finds that
PADI2 is weakly expressed in these cells (Additional
file 1, Figure S1a). Analysis of PADI2 transcript levels
in these cell lines finds that, as expected, PADI2 mRNA is
sharply elevated in the BT-474 line (Figure 2b), and is ~2
fold higher that that seen in the MCF10DCIS cells
(Additional file 1, Figure S1b) when compared to
MCF10A cells. To test whether PADI2 expression is
elevated in HER2/ERBB2 expressing cells in vivo, we
next measured PADI2 mRNA in normal murine
mammary epithelium and in primary mammary
tumors collected from MMTV-neu mice. Results in-
dicate PADI2 mRNA levels are ~15-fold higher in
the HER2/ERBB2 overexpressing tumors compared
to normal mammary tissue from littermate controls
(Figure 2c). The ~15-fold increase in PADI2 expres-
sion found in our study, compared to the ~4-fold in-
crease found in the previous study [12], may simply
reflect technical differences between the studies as
we utilized TaqMan qRT-PCR compared to micro-
array analysis. We also investigated the level of
PADI2 mRNA in MMTV-Wnt-1 mice, which is a
basal mouse model of breast cancer [36-38]. The
MMTV-Wnt-1 model is unique in that it exhibits
discrete steps in mammary tumorigenesis; the mam-
mary glands are first hyperplastic, and then advance
to invasive ductal carcinomas, finally culminating in fully
malignant carcinomas that undergo metastasis [39]. Inter-
estingly, we see that PADI2 levels are higher in the hyper-
plastic mammary glands (Figure 2c) when compared to
normal mammary glands; however, the levels are less than
those seen in the MMTV-neu tumors and are further
reduced in the fully malignant MMTV-Wnt-1 tumors.
To strengthen the hypothesis that PADI2 is primarily
expressed in luminal breast cancer cell lines and is coex-
pressed with HER2/ERBB2, we next investigated PADI2
mRNA levels by querying RNA-seq datasets collected
from 57 breast cancer cell lines. A summary of PADI2
expression in these lines is shown in the Additional file
2, Figure S2, with the most significant difference (p =
3.59 × 10-5) in PADI2 expression across subtypes being
found when luminal lines were compared with all non-
luminal subtypes (Figure 2d). We then quantified the
correlation between PADI2 and HER2/ERBB2 expression
across the 57 cell lines. Results show that the correlation
between PADI2 and HER2/ERBB2 overexpression is
highly significant across the luminal, basal-NM (non-
malignant), and claudin-low cell lines (rho = 0.828, p =
2.2 × 10-16) (Figure 3). Interestingly, a correlation be-
tween PADI2 and HER2/ERBB2 expression was not
observed across the basal cell lines. In contrast, a signifi-
cant anti-correlation was observed (rho = −0.495, p =
0.045), suggesting that the expression of these genes may
be regulated by different mechanisms in these cell lines.
Lastly, we queried the RNA-seq dataset to determine
which genes were best correlated with HER2/ERBB2 and
PADI2 expression in the luminal, basal-NM, and claudin-
low lines to assess the relative strength of their coexpres-
sion. Only a single gene (CCL17) was as correlated with
PADI2 as HER2/ERBB2 (rho = 0.832, p = 2.2 × 10-16),
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and PADI2 represented the 13th most highly correlated
gene with HER2/ERBB2 (Table 1), thus suggesting co-
regulation between HER2/ERBB2 and PADI2.
Inhibition of PADI activity reduces cellular proliferation in
breast cancer cell lines
To investigate whether PADI2 expression is important
for breast cancer cell proliferation, we next tested
whether the pharmacological inhibition of PADI2 activ-
ity negatively affects the growth of tumor cells in vitro.
We utilized the small molecule inhibitor Cl-amidine for
this study because we have previously shown that this
drug binds irreversibly to the active site of PADIs,
thereby blocking activity in vitro and in vivo [40]. Cl-
amidine functions as a “pan-PADI” inhibitor as it blocks
the activity of all active PADI family members (i.e.
PADIs 1–4) with varying degrees of specificity [41]. Cul-
tures from the MCF10AT cell line series were treated
with 10 μM, 50 μM, or 200 μM of Cl-amidine, and the
effects of the inhibitor on cell proliferation were quanti-
fied. Results show a dose-dependent decrease in the
growth of all cell lines. Additionally, given that 200 μM
**
**
*
0
2
4
6
8
10
12
14
16
18
R
el
at
iv
e 
PA
DI
2 
m
RN
A
a
PADI2
β-actin
HER2
b
*
*
*
0
50
100
150
200
250
R
el
at
iv
e 
PA
DI
2 
m
RN
A
c
d
** *
Figure 2 PADI2 expression is elevated in luminal B BT-474 cells, murine MMTV-neu tumors, and is correlated with the luminal subtype.
(a) Four different breast cancer cell lines were selected to represent the common subtypes of breast cancer: MCF7 (luminal A), BT-474 (luminal B),
SK-BR-3 (HER2/ERBB2+), and MDA-MD-231 (basal). PADI2 expression is highest in both of the HER2/ERBB2 overexpressing cell lines, with the
highest level seen in the luminal B BT-474 cells (ER+/PR+). (b) Relative PADI2 mRNA levels in the cell lines compared to MCF10A. (c) Tumors from
MMTV-neu mice (luminal subtype) show a ~15-fold increase in PADI2 compared to normal mammary tissue. Both MMTV-Wnt-1 hyperplastic
mammary tissue and tumors (basal subtype) show elevated levels of PADI2 compared to normal mammary tissue; however, PADI2 expression
levels in MMTV-Wnt-1 tumors are ~10-fold less than those seen in the MMTV-neu tumors. PADI2 mRNA levels were determined by qRT-PCR
(TaqMan) using MCF10A cells as a reference and GAPDH normalization. Expression levels were analyzed using the 2 -ΔΔ C(t) method, and data are
expressed as the mean ± SD from three independent experiments (* p < 0.05, ** p < 1 × 10-6). (d) RNA-seq analysis of 57 breast cancer cell lines
shows that PADI2 expression is significantly higher in luminal lines versus basal (* p = 0.007) and higher in basal versus basal-NM/claudin-low
(** p = 0.002).
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Cl-amidine decreased the growth of MCF10DCIS cells
by 75% (Figure 4a), this cell line appeared to be particu-
larly affected by the inhibitor. Given the high level of
PADI2 expression in the MCF10DCIS line, this finding
suggests that PADI2 is likely playing an important role
in the growth of MCF10DCIS cells. Importantly, while
Cl-amidine also suppressed the growth of MCF10DCIS
cells at lower concentrations, these doses did not inhibit
the growth of the non-tumorigenic “normal” MCF10A
line. These data suggest that Cl-amidine is not generally
cytotoxic. In addition, citrulline levels in the Cl-amidine
treated MCF10DCIS cells were significantly reduced,
suggesting that the inhibitory effect of Cl-amidine was
specifically due to the blockade of PADI activity
(Figure 4b). In order to test the potential anti-tumor effi-
cacy of Cl-amidine in a physiological model, we investi-
gated the effects of this inhibitor on the growth of
MCF10DCIS tumor spheroids. Spheroids grown from
this cell line have been shown by others to form acinar-
like structures that closely recapitulate the comedo-
DCIS lesions that form in MCF10DCIS xenografts
[18,20,42]. Results from our studies found that Cl-
amidine treatment significantly reduces tumor spheroid
diameter (Figures 4c). Representative images of the
effects of Cl-amidine on the growth of MCF10DCIS
monolayers and spheroids are shown in Figure 4d.
Cl-amidine alters the expression of cell cycle associated
genes and induces apoptosis
The observed effects of Cl-amidine on cell proliferation
suggested that this drug might affect tumor growth by
altering the expression of genes involved in cell cycle
progression. To test this hypothesis, mRNA from the Cl-
amidine treated and control MCF10DCIS cells was
examined for the expression of cell cycle associated
genes using the RT2 Profiler PCR Cell Cycle Array via
qRT-PCR. Using a threshold value of 2-fold expression
change and a statistical significance of p < 0.05, we
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found that Cl-amidine affected the expression of a sub-
set of genes (for the full unsorted list see Additional file
3, Table S1), with the top 10-upregulated and -downre-
gulated genes presented in Table 2. Importantly, previ-
ous studies have shown that increased expression of
GADD45α, the second most highly upregulated gene in
our study, leads to cell cycle arrest and apoptosis in a
range of cell types, including breast cancer cells [43].
This observation suggested that, in addition to affecting
cell cycle gene expression (e.g. p21), Cl-amidine might
also alter MCF10DCIS cell growth by inducing apop-
tosis. To test this hypothesis, we next treated MCF10A
and MCF10DCIS cells with increasing concentrations of
Cl-amidine for 4 days. Cells were fixed and labeled with
anti-activated Caspase-3 antibody or DAPI, and then
analyzed by flow-cytometry. Results show that Cl-
amidine treatment significantly increased the percent of
apoptotic MCF10DCIS cells in a dose-dependent man-
ner (Figure 4e). In contrast, the MCF10A cells were
largely unaffected. Furthermore, we also show that treat-
ment of MCF10DCIS cells with Cl-amidine appears to
induce cell cycle arrest in S-phase (Figure 4f ). Lastly, we
wanted to see whether the increase in apoptosis occurs
earlier after treatment, so we tested the cells again fol-
lowing 2 days of treatment, but were unable to see any
effect (Additional file 4, Figure S3a). However, this was
not surprising, as the effects of Cl-amidine are most pro-
nounced after 3 days of treatment (data not shown).
Taken together, it appears that Cl-amidine treatment
after 4 days leads to S-phase coupled apoptosis, which is
an intrinsic mechanism that prevents DNA replication
of a damaged genome in a mammalian cell [44]. We also
tested the effects of Cl-amidine on HER2/ERBB2 overex-
pressing cell lines BT-474 and SK-BR-3. Again, we see a
reduction in cell growth (Figure 5a) and an increase in
apoptosis (Figure 5b) that is coupled to S-phase cell
cycle arrest (Figure 5c) for both BT-474 and SK-BR-3.
These results show that Cl-amidine is effective in inhi-
biting the growth of luminal-HER2/ERBB2+ cell lines,
BT-474 and SK-BR-3, and agree with previously reported
data on Cl-amidine inhibition of growth in MCF7 cells
[8,9,11,45]. We wanted to test whether there would be
any effect on a basal cell line, and chose MDA-MB-231
for comparison. Surprisingly, we see an effect on both
cell growth and apoptosis (Additional file 4, Figure S3b
and c), albeit a smaller effect on apoptosis than we see
in BT-474 and SK-BR-3. While this is interesting, and
perhaps suggests the expression of a different PADI fam-
ily member in this basal cell line, we have focused on
PADI2 expressing cancers for this study, which are pre-
dominantly luminal and HER2/ERBB2 expressing. Taken
together, these results suggest that Cl-amidine blocks
the growth of MCF10DCIS cells by inducing cell cycle
arrest and apoptosis. This prediction is supported by our
previous finding that Cl-amidine can also drive apoptosis
in lymphocytic cell lines in vitro [3]. Importantly, the
lack of an apoptotic effect in MCF10A cells suggests that
Cl-amidine may primarily target tumor cells for killing.
Consistent with this possibility is the fact that Cl-
amidine did not affect the growth of non-tumorigenic
NIH3T3 cells and HL60 granulocytes [11].
PADI2 is highly expressed in the luminal epithelium of
xenograft tumors derived from MCF10DCIS cells
Given that PADI2 expression is elevated in the
MCF10DCIS cell line, we investigated PADI2 expression
and localization in primary tumors derived from
MCF10DCIS-injected mouse xenografts. Previous stud-
ies have shown that when MCF10DCIS cells are injected
into the mammary fat-pad of immunodeficient nude
(nu/nu) mice, tumors develop within 2–3 weeks. These
tumors faithfully recapitulate the human comedo-DCIS
condition, with the basement membrane limiting duct-
like structure being comprised of an outer myoepithelial
layer, an inner layer of luminal epithelial cells, and a cen-
tral necrotic lumen [18,19,46,47]. We chose to use sub-
cutaneous injections instead of orthotopic or intraductal
[48] methods, as previous work by Hu et al. showed that
the progression and phenotype of the MCF10DCIS
tumors grown subcutaneously in the mammary fat pad
were highly similar to human high-grade comedo-DCIS
tumors [19]. In our study, we found that PADI2 protein
expression was restricted to the luminal epithelium of
the duct-like structures in the MCF10DCIS xenografts,
and was not observed in the stromal tissue or the
Table 1 Top 13 genes correlating with HER2/ERBB2
expression
Symbol Description rho
PGAP3 Post-GPI attachment to proteins 3 (PERLD1) 0.941
CREB3L3 CAMP responsive element binding protein 3-like 3 0.927
C2orf54 Chromosome 2 open reading frame 54 0.860
EFCAB4A EF-hand calcium binding domain 4A 0.857
ARHGAP8 Rho GTPase activating protein 8 0.852
GRB7 Growth factor receptor-bound protein 7 0.851
TMEM210 Transmembrane protein 210 0.849
CLDN4 Claudin 4 0.847
MB Myoglobin 0.846
ELF3 E74-like factor 3 (ets domain transcription factor,
epithelial-specific )
0.842
TRIM3 Tripartite motif containing 3 0.839
PRSS8 Protease, serine, 8 0.829
PADI2 Peptidylarginine deiminase, type II 0.828
Genes identified by RNA-seq to be upregulated in HER2/ERBB2+ breast
cancers were tested for correlation (Spearman’s rho) and the top 13 genes are
ranked from top to bottom, with PADI2 exhibiting the 13th strongest
correlation with HER2/ERBB2 overexpression.
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necrotic core (Figure 6a, panel I and II). At the subcellu-
lar level, PADI2 appears to be expressed in both the
cytoplasmic and nuclear compartments of luminal epi-
thelial cells (Figure 6a, panel II). This observation sup-
ports our recent findings that PADI2 can be targeted to
the nucleus of both human normal mammary tissue and
breast cancer cells [49] and regulate gene activity via
citrullination [49,50].
Next, we examined whether the observed correlation
between PADI2 and HER2/ERBB2 expression also
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occurred in vivo. We found that both HER2/ERBB2 and
PADI2 were expressed within the luminal epithelium of
MCF10DCIS tumors (Figure 6a, panel III and IV). Inter-
estingly, a previous report by Behbod et. al. found low
levels of HER2/ERBB2 in MCF10DCIS tumors that were
grown intraductally. The disparity between this data and
our data may be due to differences in the microenviron-
ment. We then quantified PADI2 mRNA in the
MCF10DCIS xenografts by qRT-PCR, and found that
PADI2 levels were significantly higher in the tumors when
compared to monolayer cultures (Figure 6b). We also car-
ried out immunofluorescence (IF) analysis of these tumors
to examine PADI2 intratumoral localization, and found that
PADI2 protein expression appears entirely limited to
cytokeratin-positive luminal epithelial cells (Figure 6c, panel
I and III, and Additional file 5, Figure S4), while no detect-
able PADI2 signal was observed in the p63 positive myoe-
pithelial cells (Figure 6c, panel IV and VI, and Additional
file 5, Figure S4).
Treatment of MCF10DCIS xenografts with Cl-amidine
suppresses tumor growth
Given the inhibitory effects of Cl-amidine on MCF10-
DCIS monolayer and spheroid growth, we next tested
whether the treatment of mice with this inhibitor
would suppress the growth of MCF10DCIS-derived tu-
mors. For this study, mouse fat-pads were injected with
MCF10DCIS cells (1 × 106) and the tumors were al-
lowed to establish and grow for ~2 weeks as described
previously [18-20,46]. Mice were randomly assigned into
treatment or control groups and administered daily
intra-peritoneal (IP) injections of either Cl-amidine (50
mg/kg/day) or vehicle (PBS). Note, that the choice of
dose and route of administration were based on the pre-
vious demonstration that Cl-amidine reduces disease se-
verity in the murine collagen induced arthritis model of
rheumatoid arthritis [5]. Treatment continued for 14
days, at which point the tumors were harvested. Results
from our xenograft study show that Cl-amidine treat-
ment (n = 7/group) caused a significant reduction in the
size of the tumors (Figures 7a). Moreover, the analysis of
tumor morphology by H&E and PAS staining shows
that, while tumors from the sham-injected group dis-
played an advanced, potentially invasive, tumor pheno-
type (Figure 7b, panel II), tumors from the Cl-amidine
treated group (Figure 7b, panel I) were much more be-
nign in appearance. Furthermore, the basement mem-
brane of Cl-amidine treated tumors remained largely
Table 2 Top 10 cell cycle genes up- and down-regulated in MCF10DCIS cells after Cl-amidine treatment
Symbol Description Fold change p-value
Genes upregulated
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 17.68 1.06E-03
GADD45A Growth arrest and DNA-damage-inducible, alpha 13.53 3.57E-03
ATM Ataxia telangiectasia mutated 9.61 6.91E-04
DIRAS3 DIRAS family, GTP-binding RAS-like 3 8.87 2.41E-04
HERC5 Hect domain and RLD 5 8.20 2.31E-03
RAD17 RAD17 homolog (S. pombe) 7.50 2.20E-05
CUL2 Cullin 2 6.57 7.37E-04
CCNE1 Cyclin E1 6.18 5.51E-04
ATR Ataxia telangiectasia and Rad3 related 5.83 1.77E-04
CCNT2 Cyclin T2 5.68 1.15E-04
Genes downregulated
MCM5 Minichromosome maintenance complex component 5 −8.45 3.23E-02
CDK1 Cyclin-dependent kinase 1 −8.14 2.88E-03
CDC20 Cell division cycle 20 homolog (S. cerevisiae) −7.90 2.00E-06
GTSE1 G-2 and S-phase expressed 1 −6.62 4.84E-03
MCM2 Minichromosome maintenance complex component 2 −6.40 7.55E-04
MKI67 Antigen identified by monoclonal antibody Ki-67 −5.11 7.60E-05
CCNF Cyclin F −5.07 1.10E-02
BIRC5 Baculoviral IAP repeat containing 5 (Survivin) −4.49 1.10E-02
BCL2 B-cell CLL/lymphoma 2 −4.14 1.70E-05
CCND2 Cyclin D2 −3.74 3.95E-02
MCF10DCIS cells were treated with 200 μM Cl-amidine after seeding (5 × 104), and total RNA was collected 5d post-seeding. The mRNA for each group was tested
on the RT2 Profiler PCR Cell Cycle Array (SABiosciences Corporation, catalog number PAHS-020A). The PCR array was designed to study the profile of 84 human
cell cycle related genes. Using a threshold value of 2-fold expression change and a statistical significance of p < 0.05, we found that Cl-amidine affected the
expression of a subset of genes, with the top 10 up- and down-regulated genes displayed here.
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intact (Figure 7c) and had considerably less membrane
breaching and leukocyte infiltration compared to the
control group. These findings suggest that PADI2 plays
an important role in comedo-DCIS progression and that
the inhibition of PADI activity can suppress tumor pro-
gression in vivo.
Discussion
In this study, we show that PADI2 is specifically upregu-
lated during mammary tumor progression and that the
PADI inhibitor, Cl-amidine, is effective in inhibiting the
growth of PADI2 overexpressing cell lines in both 2D
and 3D cultures. In addition, we demonstrate here for
the first time that Cl-amidine is successful in suppres-
sing tumor growth in a xenograft mouse model of com-
edo-DCIS. Lastly, we document that PADI2 expression
is highly correlated with HER2/ERBB2 overexpressing
and luminal subtype breast cancers.
Given the previous correlations between PADI2 and
the HER2/ERBB2 oncogene, the goal of this study was
to carry out an initial test of the hypothesis that PADI2
plays a role in breast cancer progression. To accomplish
this, we utilized the well-established MCF10AT model
[16,17] and found that PADI2 expression was highly
upregulated in MCF10DCIS cells, a cell line that forms
comedo-DCIS lesions that spontaneously progress to in-
vasive tumors [30,46]. Our finding that PADI2 expres-
sion is highest in comedo-DCIS lesions (defined by their
necrotic centers) was perhaps not too surprising, given
the close association of PADIs with inflammatory events.
We are currently investigating the potential links be-
tween inflammatory signaling in these MCF10DCIS
lesions and PADI2 activity.
Interestingly, PADI2 expression in the MCF10AT
series coincided with HER2/ERBB2 upregulation which,
again, was not entirely unexpected given previous
reports correlating PADI2 expression with HER2/ERBB2
[15]. While we did find that HER2/ERBB2 and PADI2
protein expression correlated well across the MCF10AT
cell lines, PADI2 protein levels are particularly high in
the MCF10DCIS line, relative to HER2/ERBB2. We can-
not currently explain this finding; however, it is possible
that cell-line-specific factors are stabilizing the PADI2
transcript, thus allowing for increased protein expression
[51,52].
While our data show a potential relationship between
PADI2 and HER2/ERBB2 in the MCF10AT model, we
wanted to examine this correlation at higher resolution.
To accomplish this we queried our RNA-seq dataset of
57 breast cancer cell lines with known subtype and
HER2/ERBB2 status and found that: (a) PADI2 expres-
sion is highest in luminal cell lines and that (b) PADI2
expression is highly correlated with HER2/ERBB2 over-
expression across the basal-NM, claudin-low, and
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Figure 6 PADI2 is expressed in MCF10DCIS xenograft tumors and localizes to the luminal epithelium. (a) MCF10DCIS cells (1 × 106) were
injected subcutaneously into female nude (nu/nu) mice (Charles River) and comedo-DCIS tumors formed after 2 weeks. Tumor sections were
probed with an (I, II) anti-PADI2 (1:100) or (III, IV) anti-ERBB2 antibody (1:100), and counterstained with hematoxylin. The black arrows indicate the
luminal epithelium of the duct-like structures in DCIS tumors (I, III – 20X, scale bar = 200 μm; II, IV – 100X, scale bar = 50 μm). While the
HER2/ERBB2 staining is predominantly cytoplasmic (IV), there are some nuclei staining positively for PADI2 (II). (b) Tumors were collected; two
sections from each mouse were sampled and total RNA was isolated. PADI2 mRNA levels were determined by qRT-PCR (TaqMan) using MCF10A
cells as a reference and GAPDH normalization. PADI2 levels were higher in the tumor samples than normally found in the MCF10DCIS cells. Data
were analyzed using the 2 -ΔΔ C(t) method, and are expressed as the mean ± SD from three independent experiments (* p < 0.005).
(c) Immunofluorescence staining (40X) shows that PADI2 is expressed in the luminal but not myoepithelium cells in MCF10DCIS tumors. Tumors
were probed with anti-PADI2 (II, III, V, VI – green fluorescent signal), anti-cytokeratin (I, III – luminal marker – red fluorescent signal), and anti-p63
(IV, VI – myoepithelial marker – red fluorescent signal). Nuclei were stained with DAPI (blue fluorescent signal). The dashed arrows delineate the
luminal epithelium layer, while the dashed straight line delineates the myoepithelium layer, which is adjacent to the basement membrane. In the
merged images, the co-localization of cytokeratin and PADI2 can be seen in the luminal epithelium (III), while in contrast, PADI2 is absent from
the p63 stained myoepithelium (VI).
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luminal lines. The observation that PADI2 is upregulated
in the luminal subtype confirms previous gene expres-
sion data where PADI2 was identified as one of the top
upregulated genes in luminal breast cancer lines com-
pared to basal lines [13,14]. In order to test whether the
observed correlation between PADI2 and HER2/ERBB2
would be retained at the protein level, we also tested a
small sample of cell lines representing the four common
breast cancer subtypes and found that PADI2 expression
was only observed in the HER2/ERBB2+ BT-474 and
SK-BR-3 lines. However, we did observe some discord-
ance seen between PADI2 transcript and protein levels,
but we predict this difference may be due to post-
transcriptional regulatory mechanisms. This prediction
is based, in part, upon the observation that PADI2
possesses a long 3’UTR [53] that contains several AU-
rich elements [54,55] that have been shown to bind the
stabilizing regulatory factor HuR [56]. HuR binding has
been shown to enhance the stability of mRNAs involved
in proliferation [57-59], while also playing a role in
breast cancer, as cytoplasmic accumulation of HuR pro-
motes tamoxifen resistance in BT-474 cells [60] and the
stability of HER2/ERBB2 transcripts in SK-BR-3 cells
[52]. Interestingly, from these studies, the level of HuR
was reported to be high in both BT-474 and SK-BR-3
cells, while it was relatively low in MCF7 cells. It is im-
portant to note that while we observed low levels of
PADI2 protein expression in MCF7 (Additional file 1:
Figure S1a), recent work from our lab has confirmed the
expression of PADI2 in MCF7 cells [49,50].
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We also examined two mouse models of mammary
tumorigenesis, the luminal MMTV-neu and the basal
MMTV-Wnt-1, and found that, as predicted, PADI2
levels are highest in the HER2/ERBB2 overexpressing
MMTV-neu mice compared to normal mammary tissue
and to hyperplastic and primary MMTV-Wnt-1 tumors.
Taken together, these findings indicate that PADI2 is
predominantly expressed in luminal epithelial cells, and
that there appears to be a strong relationship between
PADI2 and HER2/ERBB2 expression in breast cancer.
Subsequent studies are now underway to test whether
PADI2 plays a functional role in HER2/ERBB2 driven
breast cancers, potentially by functioning as an inflam-
matory mediator.
Previous studies have shown that the inhibition of
PADI enzymatic activity by Cl-amidine is effective in
decreasing the growth of several cancer cell lines (i.e.
HL-60, HT-29, U2OS, and MCF7 cells), and that admin-
istering the drug in combination with doxorubicin or the
HDAC inhibitor SAHA can have synergistic cytotoxic
effects on cells [8,9,11,45]. Cl-amidine is highly specific
for all PADI enzymes, with dose-dependent cytotoxicity
and little to no effect in non-cancerous cell lines (i.e. HL-
60 granulocytes and NIH3T3 cells) [11]. Our studies ex-
pand on these previous results by showing that Cl-
amidine suppresses the growth of the transformed lines
of the MCF10AT model, especially the MCF10DCIS cell
line, in both 2D and 3D cultures. In addition, we show
for the first time that Cl-amidine is successful in treating
tumors in vivo using a mouse model of comedo-DCIS
from xenografted MCF10DCIS cells. Given that the loss
of basement membrane integrity is an important event
during the progression of DCIS to invasive disease, it is
significant that Cl-amidine treated xenografts maintain
their basement membrane integrity and show reduced
leukocytic infiltration across the basement membrane
compared to the control group. These observations sug-
gest that Cl-amidine treatment might enhance the ability
of tumor ductular myoepithelial cells to deposit continu-
ous and organized basement membranes.
While we chose the subcutaneous model of MCF10DCIS
tumorigenesis, future studies on the effect of Cl-amidine
could examine alternate methods of transplantation,
such as the previously described intraductal method
[48]. In addition, different models of DCIS could be
examined, such as xenografted SUM-225 cells, which
show high HER2/ERBB2 and PADI2 levels (see Figure 3
for relative levels). Of note, we found that while Cl-
amidine suppressed tumor growth, the drug was well tol-
erated by mice in this study. Similarly, our previous work
found that doses of Cl-amidine up to 75 mg/kg/day in a
mouse model of Colitis [3], and up to 100 mg/kg/day in a
mouse model of RA [5], were well-tolerated without side
effects. Further work into studying the pharmacokinetics
and biodistribution of Cl-amidine, or perhaps the devel-
opment of an isozyme specific inhibitor of PADI2, will
be an important step in helping to find a potent drug for
the treatment of DCIS patients.
The actual mechanisms by which Cl-amidine reduces
cellular proliferation have yet to be fully elucidated,
though evidence here suggests that PADI2 may play a
role (direct or indirect) in regulating the expression of
both cell cycle and tumor promoting genes. Previous
reports have shown that Cl-amidine effectively upregu-
lates a number of p53-regulated genes, including p21,
PUMA, and GADD45 [8,45]. Our qRT-PCR cell cycle
array results confirm that two of these genes, p21
and GADD45α, are upregulated after treatment of
MCF10DCIS cells with Cl-amidine by 17.68- and 13.53-
fold, respectively. Furthermore, we have identified add-
itional genes downregulated by Cl-amidine, including
MKI67, MCM5, and MCM2, each with known functions
in cancer progression. We have also quantitatively ana-
lyzed for apoptosis levels (Caspase-3) after Cl-amidine
treatment via flow-cytometry, and see a dose-dependent
decrease in proliferation and increase in apoptosis. More-
over, we also show that the cells arrest in S-phase after Cl-
amidine treatment, thus leading to S-phase coupled apop-
tosis, which is a known response to DNA damage [44].
Taken together, the observed inhibitory effects of Cl-
amidine on tumor growth may be due to the suppression
of genes involved in oncogenesis and the activation of genes
involved in apoptosis, though additional work is needed to
define the mechanisms behind these potential relationships.
Conclusions
In summary, we provide here an important new line of
evidence demonstrating that PADI2 may play a role in
the oncogenic progression of cancer and, in particular,
breast cancer. Using the MCF10AT model, we show
that PADI2 is highly upregulated following transform-
ation at both the mRNA and protein level, with highest
levels in the cell line that recapitulates human comedo-
DCIS. Furthermore, we show that, across a wide array
of breast cancer cell lines, PADI2 is specifically overex-
pressed in the luminal subtype, while also being highly
correlated with HER2/ERBB2 overexpression. This ob-
servation suggests that PADI2 may function as a bio-
marker for HER2/ERBB2+ lesions. Lastly, our preclinical
mouse xenograft study suggests that the PADI inhibitor,
Cl-amidine, could potentially be utilized as a therapeutic
agent for the treatment of comedo-DCIS tumors.
Additional files
Additional file 1: Figure S1. Comparative expression levels of
MCF10DCIS and HER2/ERBB2 expressing BT-474 and SK-BR-3 cell lines.
(A) Overexposure of image in Figure 2a, showing that there are low
McElwee et al. BMC Cancer 2012, 12:500 Page 14 of 17
http://www.biomedcentral.com/1471-2407/12/500
levels of PADI protein found in the MCF7 cell line. (B) MCF10DCIS PADI2
levels are about half that of BT-474 cells, with SK-BR-3 PADI2 levels being
about half that of MCF10DCIS cells. These PADI2 levels recapitulate the
relationship seen at the protein level. Total RNA was isolated from
MCF10A, MCF10DCIS, BT-474, and SK-BR-3 cell lines and PADI2 mRNA
levels were determined by qRT-PCR (TaqMan) using MCF10A cells as a
reference and GAPDH normalization. Data were analyzed using the
2 -ΔΔ C(t) method and are expressed as the mean ± SD from three
independent experiments (* p < 0.005).
Additional file 2: Figure S2. PADI2 gene-level expression compared to
distribution of all genes across 57 breast cancer cell lines. PADI2 mRNA
expression levels across 57 breast cancer cell lines were measured by
RNA-seq. PADI2 levels are shown relative to all other genes in each cell
line. PADI2 is most highly expressed in the luminal lines (26/29 above
background). PADI2 levels are significantly different in luminal cell lines
when compared to all non-luminal cell lines (p = 3.59 × 10-5).
Additional file 3: Table S1. Complete list of genes from RT2 Profiler
PCR Cell Cycle Array with fold change values for MCF10DCIS cells after
Cl-amidine treatment. MCF10DCIS cells were treated with 200 μM Cl-
amidine and RNA collected 5d post-seeding. The RT2 Profiler PCR Cell
Cycle Array (SABiosciences Corporation, catalog number PAHS-020A)
profiles the gene expression of 84 human cell cycle-related genes.
Additional file 4: Figure S3. Flow-cytometry analysis of apoptosis in
MCF10A and MCF10DCIS cell lines, and both proliferation/
cell-growth and apoptosis in MDA-MB-231 cells. (A) MCF10A and
MCF10DCIS cells were treated with different concentrations of Cl-amidine
(0 μM, 200 μM, and 400 μM) and 10μg/mL Tunicamycin, and analyzed by
flow-cytometry. Data represents percent apoptotic cells (cleaved
Caspase-3 positive) after 2d and are expressed as the mean ± SD from
three independent experiments (* p < 0.05, ** p < 0.001).
(B) MDA-MB-231 cells were treated with increasing concentrations of
Cl-amidine (0 μM, 100 μM, 200 μM, and 400 μM) over 4d and analyzed
by flow-cytometry. Cell counts (DAPI) show a dose-dependent decrease
in the growth (* p < 0.001). (C) Apoptosis levels (cleaved Caspase-3
positive) significantly increase over the control only after treatment with
400 μM of Cl-amidine. Tunicamycin (10μg/mL ) is shown as a control for
apoptosis (* p < 0.01). Data are expressed as the mean ± SD from three
independent experiments.
Additional file 5: Figure S4. Immunofluorescence staining of
MCF10DCIS xenografts for PADI2, luminal epithelium
(pan-cytokeratin), and myoepithelium (p63). (A) MCF10DCIS cells
(1 × 106) were injected subcutaneously into female nude (nu/nu) mice
(Charles River) and comedo-DCIS tumors formed after 2 weeks. Tumors
were probed with anti-PADI2 (green fluorescent signal), anti-cytokeratin
(luminal marker – red fluorescent signal), and anti-p63 (myoepithelial
marker – red fluorescent signal). Nuclei were stained with DAPI (blue
fluorescent signal). Immunofluorescence staining (63X) shows that PADI2
is expressed in the luminal but not myoepithelium cells in MCF10DCIS
tumors. In addition, there is some evidence for PADI2 expression in the
nucleus.
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